Hydration & Moisture: Market Positioning Guide

Overview #

Hydration is the most crowded claim space in skincare. Every brand has a moisturizer. The question we get from brand partners isn’t “can you make a hydrating product” — it’s “how do we make ours mean something.” That’s a positioning problem before it’s a formulation problem, and the two are more connected than most brand owners realize. The ingredients you choose, the concentrations you run, and the delivery system you use all determine what you can defensibly say on pack — and what will get flagged by a regulatory reviewer in the EU or a savvy consumer on TikTok.

The Claims Landscape: What’s Defensible and What Isn’t #

Let’s be direct about how claims work in this category. “Hydrating” is a cosmetic claim. “Restores the skin barrier” is a cosmetic claim. “Treats dry skin disease” is not — that’s a drug claim in most markets, and we flag it immediately when it shows up in a brief. The line sounds obvious until you’re writing copy at 11pm before a launch deadline.

The EU Cosmetics Regulation 1223/2009 sets the framework for what’s permissible in European markets, and it’s stricter on implied therapeutic claims than most brand owners expect. The FDA Cosmetics Guidelines draw a similar line in the US, though enforcement has historically been lighter. In China, the NMPA Cosmetic Regulation now requires substantiation dossiers for “special cosmetics” claims — and barrier repair language is increasingly being scrutinized under that lens.

What we tell brand partners: anchor your claims to mechanism, not outcome. “Delivers hyaluronic acid to the stratum corneum” is defensible. “Eliminates dry skin” is not. “Supports the skin’s natural moisture retention” — defensible. “Cures dehydration” — no.

The practical implication for formulation: if you want to use clinical language on pack, you need clinical data that matches your actual formula. We’ve had brands come to us with a competitor’s study and ask us to replicate the formula. That’s not how it works. The study has to be run on your product, at your concentration, in your delivery system.

Ingredient Differentiation: Where the Real Positioning Happens #

This is where most brands get it wrong. They brief us on “hyaluronic acid serum” and think the differentiation is the HA molecular weight. Sometimes it is. More often, it isn’t.

Here’s the honest breakdown of the main hydration actives we work with and what they actually deliver:

The table above is how we think about brief intake. When a brand says “we want a barrier repair serum,” we’re immediately asking: ceramide-led or lipid-complex-led? What’s the target pH? What’s the packaging — because ceramides in a jar with a wide mouth oxidize faster than in an airless pump.

For deeper context on how we approach barrier-focused formulation, see our Barrier Repair & Sensitive Skin formulation docs.

One thing worth flagging: polyglutamic acid is having a marketing moment right now. We’re not convinced the clinical evidence is strong enough to justify the premium positioning some brands are building around it. The mechanism is real — PGA does inhibit hyaluronidase — but the head-to-head data against well-formulated HA systems is thin. We use it, but we’re honest with partners about what it can and can’t support on pack.

The Clinical Language Question #

Brand owners ask us this constantly: “What can we actually say?” The answer depends on what data you have, and what data you’re willing to generate.

The most defensible clinical language in the hydration category comes from corneometry and TEWL (transepidermal water loss) measurements. These are standard, relatively inexpensive, and accepted by most regulatory bodies as substantiation for cosmetic hydration claims. A typical corneometry study runs 20–30 subjects, 4–8 weeks, with measurements at baseline, 2 weeks, and 4 weeks. That’s enough to support “clinically tested to improve skin hydration” if the results are statistically significant.

One study we reference internally: a double-blind, randomized controlled trial (n=44, 8 weeks) comparing a ceramide-HA combination serum against a vehicle control showed a 34% improvement in corneometer readings at week 4 and a 28% reduction in TEWL at week 8. The formula used ceramide NP at 0.4%, sodium hyaluronate (mixed MW) at 1.2%, and glycerin at 5%. That’s a real result from a real formula — not a supplier deck number. It’s the kind of data that supports “clinically proven to strengthen the skin barrier” in most markets.

What it doesn’t support: “repairs damaged skin barrier” (drug territory in some markets), “treats eczema” (definitely drug territory), or “dermatologist recommended” without an actual dermatologist endorsement program.

The SCCS Scientific Opinion framework is worth reading if you’re building a dossier for EU market entry. It’s dense, but it tells you exactly what substantiation standard the EU expects.

Where Most Brands Get This Wrong #

Honestly, the biggest positioning mistake we see is conflating hydration with barrier repair. They overlap, but they’re not the same claim, and they don’t require the same formula.

A humectant-heavy serum — high glycerin, high HA — will score well on corneometry at 2 hours post-application. It may do almost nothing for TEWL. If your brand story is about “repairing the barrier,” that formula won’t support the claim, no matter how good the marketing copy is. We’ve had to have that conversation with three separate brand partners in the last year alone.

The other failure mode we see regularly: brands brief us on a “clean” formula with no silicones, no PEGs, and a short ingredient list — then expect the same sensory profile as a conventional moisturizer. It doesn’t work that way. Silicones do real functional work in moisturizer texture. When you remove them, you need to replace that functionality with something — usually a combination of plant-derived emollients and a rheology modifier — and that adds cost and complexity. A lot of clean beauty brands underestimate how much formulation work goes into making a short INCI list feel elegant.

Scale-up is where this gets painful. We had one project — a “clean” barrier cream with a 12-ingredient INCI — that performed beautifully at 500g lab scale. At 200kg production, we saw phase separation in the emulsion by week 6 of stability testing. The culprit was a botanical extract that behaved differently at production temperature. We reformulated with a different emulsifier system and it held. But that added six weeks to the timeline and cost the brand a launch window.

This is still evolving territory. What counts as “clean” varies by market, by retailer, and by year. What Sephora US accepts today may not match what Douglas Germany expects next year.

OEM Capability Comparison: What Actually Matters #

Brand owners evaluating OEM partners often ask us how our capabilities compare to European or US-based contract manufacturers. It’s a fair question. Here’s our honest take.

On raw material access: we source ceramides, HA grades, and peptide actives from the same global suppliers — Evonik, DSM-Firmenich, Givaudan — that Western CMOs use. Lead times are often shorter because we’re geographically closer to the Asian supply chain for many of these materials. For specialty actives like fermented ingredients or traditional botanical extracts, our sourcing network is genuinely stronger.

On regulatory support: we can prepare dossiers for NMPA Cosmetic Regulation filing, EU CPNP notification, and FDA OTC monograph compliance. We work with third-party EU Responsible Persons for brands entering European markets. What we can’t do is replace a local regulatory consultant for complex market-specific questions — and we tell brands that upfront.

On cost: a well-formulated ceramide-HA serum at MOQ 3,000 units typically runs 30–45% lower COGS from our facility compared to equivalent European CMO quotes we’ve seen. That gap narrows for highly specialized formats — airless pump packaging adds $0.40–$0.80 per unit regardless of where you manufacture, and that cost is real at MOQ 1,000.

On stability infrastructure: we run ICH Q1A-aligned stability protocols — 40°C/75% RH accelerated, 25°C/60% RH long-term — as standard. See ICH Stability Guidelines for the full framework. Most of our stability chambers are third-party calibrated quarterly.

For brands building a face serum line in the hydration category, the capability question usually comes down to: can you hit the sensory target, can you support the claims, and can you hold stability? Those are the three things we get evaluated on.

Formulation Notes for Brand Partners #

What market? What are you expecting on-pack? Those are the first two questions we ask when a hydration brief lands on our desk.

If you’re targeting the US mass-premium channel — think Ulta, Target — the brief usually calls for a glycerin-HA base with a ceramide story, a clean-ish INCI, and a price point that supports a $28–$45 retail. We can build that. The formulation is relatively straightforward; the positioning work is in the claims language and the clinical substantiation.

If you’re targeting EU specialty retail or pharmacy, the regulatory bar is higher and the sensory expectations are different. European consumers tend to prefer lighter textures and are more sensitive to fragrance. We’d typically run a fragrance-free or near-fragrance-free formula, lean on beta-glucan or oat extract for the “soothing” story, and make sure the dossier is clean before we talk about claims.

If you’re targeting the Korean or Japanese market — or building a K-beauty-adjacent brand for Western consumers — the brief changes again. Layering textures, essence-to-serum formats, and fermented ingredient stories are all in play. That’s a different formulation brief entirely.

The one thing that’s consistent across all markets: don’t brief us on a claim and then ask us to reverse-engineer a formula to support it. Start with what you want the product to do, and we’ll tell you what claims that formula can defensibly carry.

Frequently Asked Questions #

Q: We want to say “72-hour hydration” on pack — can you actually substantiate that?

Yes, but it requires a specific study design. You need corneometry measurements at 24, 48, and 72 hours post-single-application, on at least 20 subjects. We can help you set that up with a third-party CRO. Without that data, “72-hour hydration” is a claim we won’t put in a brief — it’s the kind of thing that gets flagged in EU market review.

Q: What’s the difference between 1% HA and 2% HA — is more always better?

Not really. Above 1.5%, high-MW sodium hyaluronate starts to create a tacky, pill-y texture that most consumers dislike. We typically run 0.5–1.0% high-MW HA and layer in 0.1–0.3% low-MW HA for depth. The total HA number on your marketing deck can still be meaningful — it’s the ratio and MW blend that does the real work.

Q: Can we combine ceramides and retinol in the same formula?

You can, but the formulation constraints are significant. Ceramides need a lipid-rich, slightly acidic environment (pH 5.0–5.5). Retinol is stable in that range, but the emulsifier system has to be chosen carefully to avoid retinol degradation. We’ve done it successfully, but it adds 4–6 weeks to the stability timeline. See our Retinoid Technology docs for more on that.

Q: Our retailer wants “dermatologist tested” on pack — what does that actually require?

It requires a dermatologist to have tested it. Specifically, a patch test or RIPT (Repeat Insult Patch Test) conducted or supervised by a licensed dermatologist, with a report you can produce if challenged. The test itself typically runs 4–6 weeks and costs $2,000–$5,000 depending on the CRO. It’s not a big investment relative to a launch, and it’s worth doing.

Q: We’re a small brand — MOQ 500 units. Can we still get a properly substantiated hydration formula?

At MOQ 500, your options narrow. We can formulate from our existing validated bases, which keeps development cost down and means the base formula already has stability data. You won’t have product-specific clinical data at that volume — the study cost doesn’t make sense below roughly MOQ 3,000. But you can still use ingredient-level claims (“contains hyaluronic acid,” “with ceramides”) that are defensible without product-specific studies.

Have a product concept in mind? Contact our formulation team to request a complimentary brief review.